Digital health company Glooko acquired Germany-based company xbird, a medical AI company with JITAI (Just In Time Adaptive Intervention) technologies to predict patient behavior and offer behavioral changes accordingly to improve outcomes for patients with diabetes. a Medical AI Company
Interviews with Glooko's previous CEO, new CEO and a Novo Nordisk executive show that the two company's messaging around the development of a smart insulin pen is not aligned.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Russ Johannesson pushed back on the idea that he is the CEO whose sole goal is to take the company to an exit, opined on competitors like Livongo, and said Glooko is the connective tissue across the diabetes management ecosystem.
During the Redox and Matter Healthcare Interoperability Summit in Chicago, a panel of investors and executives discussed where we are and where we're going in terms of interoperability in healthcare.
Glooko also picked up investments from machine learning investor Georgian Partners and diabetes medical device business Insulet Corp.
The collaborations are part of a push by Fit4D to scale its business across pharma, payers, and ACO segments.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The move gives Glooko another partner with global reach and reflects the broader trend of connected device companies building diverse ecosystems of these devices.
The deal gives the Danish pharmaceutical company a consumer-focused technology platform to build on. In return, Glooko gains access to Novo Nordisk's extensive customer base and deep library of educational content.
In the latest demonstration of the consolidation trend in digital health, Glooko and Diasend have said they will merge under Glooko's brand name.
Glooko, a digital health buiness, has added a series of devices to a recently launched platform designed to aggregate not only data from blood-gluose meters and insulin pumps.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Glooko, a digital health company that helps users unlock data from their glucose meter and wearables to better manage patients, has raised a Series B round led by Medtronic and Canaan Partners. The Social + Capital Partnership and Samsung’s venture investment arm also participated in the round. Glooko added Samsung as a strategic partner last […]
Glooko, a mobile health company specializing in diabetes, has produced a practical answer to the question of how to make the most of digital health data aggregation tools. It has developed a way to aggregate data from fitness wearables and biometric devices in collaboration with Joslin to help users avoid triggering hypoglycemic events, according to […]
Glooko, Inc. received an FDA nod for its Android compatible version of its next-generation diabetes management system. According to a company statement, this system is now “the only FDA-cleared mobile diabetes management system that supports the transfer of blood glucose data direct from dozens of compatible glucose meters into many Android devices.” The cloud-based management […]